Results 21 to 30 of about 815 (103)

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

CPT: Pharmacometrics & Systems Pharmacology, 2023
Effective antiviral treatments for coronavirus disease 2019 (COVID‐19) are needed to reduce the morbidity and mortality associated with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection, particularly in patients with risk factors for
Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie Birger, Brian M. Maas, Wei Gao, Stefan Roepcke, Susanne Sardella, Rebecca Humphrey, Sindhuri Kondragunta, Bhuvana Jayaraman, Monika Martinho, Wendy Painter, George Painter, Wayne Holman, Carisa De Anda, Michelle L. Brown, Matthew G. Johnson, Amanda Paschke, Matthew L. Rizk, Julie A. Stone   +20 more
doaj   +2 more sources

Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines [PDF]

Viruses
Feline infectious peritonitis (FIP) is a disease arising as a result of feline coronavirus infection. It used to be regarded a fatal disease, with euthanasia commonly recommended following diagnosis due to its very poor prognosis.
Séverine Tasker, Andrea M. Spiri, Katrin Hartmann, Diane D. Addie, Sándor Belák, Michèle Bergmann, Herman Egberink, Tadeusz Frymus, Regina Hofmann-Lehmann, Fulvio Marsilio, Maria Grazia Pennisi, Etienne Thiry, Uwe Truyen, Corine Boucraut-Baralon, Karin Möstl, Margaret J. Hosie   +15 more
doaj   +2 more sources

Pharmacokinetics of Molnupiravir in Cats with Naturally Occurring Feline Infectious Peritonitis [PDF]

Pathogens
Antiviral drugs like EIDD-2801 (molnupiravir; MPV) have been successfully used in the treatment of feline infectious peritonitis (FIP). The previous study of the pharmacokinetics of MPV in healthy cats showed promise for its use and safety. The objective
Petra Černá, Luke Wittenburg, Jennifer Hawley, McKenna Willis, Britta Siegenthaler, Michael R. Lappin   +5 more
doaj   +2 more sources

Clinical trial of molnupiravir with or without an oral immune stimulant as a first-line treatment of feline infectious peritonitis [PDF]

Journal of Feline Medicine and Surgery
Objectives The aim of the present study was to evaluate the efficacy of oral molnupiravir (MPV; EIDD-2801) in cats with naturally occurring feline infectious peritonitis (FIP), with a subset of cats being administered a known immune stimulant (liposome ...
Petra Černá, Steven Dow, Jennifer Hawley, McKenna Willis, Michael R Lappin   +4 more
doaj   +2 more sources

A Concise Route to MK-4482 (EIDD-2801) [PDF]

Nucleosides, Nucleotides & Nucleic Acids, 2020
A two-step route to MK-4482 (EIDD-2801, 1 ) was developed consisting of an esterification and hydroxamination of cytidine. The reactions can be conducted in either order with overall yields of 67% (first step—esterification) and 37% (first step—hydroxamination). Selective esterification of the
Natarajan Vasudevan, Grace P. Ahlqvist, Catherine P. McGeough, Dinesh J. Paymode, Flavio S. P. Cardoso, Tobias Lucas, Jule-Phillip Dietz, Till Opatz, Timothy F. Jamison, B. Frank Gupton, David Snead   +10 more
openaire   +3 more sources

Broad-Spectrum Antiviral Activity of the Orally Bioavailable Antiviral ATV014 Against Multiple Coronaviruses. [PDF]

MedComm (2020)
MedComm, Volume 6, Issue 5, May 2025.
Yang S, Li K, Zhou Q, Zhang X, Guo D.
europepmc   +2 more sources

A Concise Route to MK-4482 (EIDD-2801) from Cytidine: Part 2 [PDF]

Synlett, 2020
A new route to MK-4482 ( 1 ) was developed. The route replaces uridine with the more available and less expensive cytidine. Low cost, simple reagents are used for the chemical transformations and the yield is improved from 17% to 44%.
Snead, David R., Gopalsamuthiram, Vijayagopal, Williams, Corshai, Noble, Jeffrey, Jamison, Timothy F., Gupton, B. Frank   +5 more
openaire   +3 more sources

Unlicensed Molnupiravir is an Effective Rescue Treatment Following Failure of Unlicensed GS-441524-like Therapy for Cats with Suspected Feline Infectious Peritonitis

Pathogens, 2022
Feline infectious peritonitis (FIP) is a complex and historically fatal disease, though recent advances in antiviral therapy have uncovered potential treatments.
Meagan Roy, Nicole Jacque, Wendy Novicoff, Emma Li, Rosa Negash, Samantha J. M. Evans   +5 more
doaj   +1 more source

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Molecules, 2021
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir,
Mohd. Imran, Mandeep Kumar Arora, Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, Saleh I. Alaqel, Mohammed Kanan Alshammari, Mohammed M. Alshehri, Ahmed Subeh Alshrari, Alreshidi Mateq Ali, Ahmed Muteb Al-shammeri, Bushra Dhuhayyan Alhazmi, Aishah Ali Harshan, Md. Tauquir Alam, Abida   +13 more
doaj   +1 more source

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Antibiotics, 2021
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths.
Ching-Chi Lee, Chih-Chia Hsieh, Wen-Chien Ko   +2 more
doaj   +1 more source